Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegargiminase - Polaris Pharmaceuticals

Next Previous
Drug Profile

Pegargiminase - Polaris Pharmaceuticals

Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; ADZODI; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 09 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Memorial Sloan-Kettering Cancer Center; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
  • Class Antineoplastics; Hepatoprotectants; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Liver cancer; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Malignant-mesothelioma
  • Phase III Leiomyosarcoma; Liver cancer; Soft tissue sarcoma
  • Phase II/III Glioblastoma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-alcoholic steatohepatitis; Non-Hodgkin's lymphoma; Small cell lung cancer
  • No development reported Bladder cancer; Breast cancer; Cancer; Gastrointestinal cancer; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uveal melanoma; Viral infections

Most Recent Events

  • 09 Jun 2025 Polaris completes submission of rolling BLA for Malignant mesothelioma (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in USA (IM)
  • 30 May 2025 Pharmacodynamics data from preclinical studies in Uveal melanoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 28 May 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, First-line therapy) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top